European Journal of Cancer
Volume 45, Issue 5 , Pages 837-842 , March 2009

Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?

  • Anna Jakubowska

      Affiliations

    • International Hereditary Cancer Centre (IHCC), Department of Genetics and Pathology, Pomeranian Medical University, ul. Połabska 4, 70-115 Szczecin, Poland
    • Corresponding Author InformationCorresponding author: Tel.: +48 91 466 1532; fax: +48 91 466 1533.[Corresponding author:];
    • ,
  • Katarzyna Jaworska

      Affiliations

    • International Hereditary Cancer Centre (IHCC), Department of Genetics and Pathology, Pomeranian Medical University, ul. Połabska 4, 70-115 Szczecin, Poland
    • ,
  • Cezary Cybulski

      Affiliations

    • International Hereditary Cancer Centre (IHCC), Department of Genetics and Pathology, Pomeranian Medical University, ul. Połabska 4, 70-115 Szczecin, Poland
    • ,
  • Anna Janicka

      Affiliations

    • International Hereditary Cancer Centre (IHCC), Department of Genetics and Pathology, Pomeranian Medical University, ul. Połabska 4, 70-115 Szczecin, Poland
    • ,
  • Jolanta Szymańska-Pasternak

      Affiliations

    • International Hereditary Cancer Centre (IHCC), Department of Genetics and Pathology, Pomeranian Medical University, ul. Połabska 4, 70-115 Szczecin, Poland
    • ,
  • Marcin Lener

      Affiliations

    • International Hereditary Cancer Centre (IHCC), Department of Genetics and Pathology, Pomeranian Medical University, ul. Połabska 4, 70-115 Szczecin, Poland
    • ,
  • Steven A. Narod

      Affiliations

    • Centre for Research on Women’s Health, Toronto, Ontario, Canada
    • ,
  • Jan Lubiński

      Affiliations

    • International Hereditary Cancer Centre (IHCC), Department of Genetics and Pathology, Pomeranian Medical University, ul. Połabska 4, 70-115 Szczecin, Poland
    • ,
  • the IHCC-Breast Cancer Study Group

Received 8 August 2008 ,Revised 22 October 2008 ,Accepted 28 October 2008.

References 

  1. Górski B, Jakubowska A, Huzarski T, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer. 2004;110:683–686
  2. Górski B, Byrski T, Huzarski T, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet. 2000;66:1963–1968
  3. Górski B, Cybulski C, Huzarski T, et al. Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat. 2005;92:19–24
  4. Jakubowska A, Gronwald J, Górski B, et al. The 3’ untranslated region C>T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation. Breast Cancer Res Treat. 2007;104:67–74
  5. Jakubowska A, Gronwald J, Menkiszak J, et al. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2007;16:270–275
  6. Jakubowska A, Gronwald J, Menkiszak J, et al. Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk. J Med Genet. 2007;44:408–411
  7. Jakubowska A, Gronwald J, Menkiszak J, et al. VEGF_936_C>T 3’UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett. 2008;262:71–76
  8. Jakubowska A, Gronwald J, Menkiszak J, et al. Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res Treat. 2007;104:299–308
  9. Jakubowska A, Gronwald J, Menkiszak J, et al. Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3′ untranslated region polymorphism. BMC Cancer. 2008;8:90
  10. Jupe ER, Badgett AA, Neas BR, et al. Single nucleotide polymorphism in prohibitin 39 untranslated region and breast-cancer susceptibility. Lancet. 2001;357:1588–1589
  11. Spurdle AB, Hopper JL, Chen X, et al. Prohibitin 3′ untranslated region polymorphism and breast cancer risk in Australian women. Lancet. 2002;360:925–926
  12. Campbell IG, Allen J, Eccles DM. Prohibitin 3′ untranslated region polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:1273–1274
  13. Breast Cancer Linkage Consortium . Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997;349:1505–1510
  14. Robson M, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. J Clin Oncol. 1998;16:1642–1649
  15. White JJ, Ledbetter DH, Eddy RL, et al. Assignment of the human prohibitin gene (PHB) to chromosome 17 and identification of a DNA polymorphism. Genomics. 1991;11:228–230
  16. Nagai MA, Yamamoto L, Salaorni S, et al. Detailed deletion mapping of chromosome segment 17q12–21 in sporadic breast tumours. Genes Chromosomes Cancer. 1994;11:58–62
  17. Rastogi S, Joshi B, Dasgupta P, Morris M, Wright K, Chellappan S. Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes. Mol Cell Biol. 2006;26:4161–4171
  18. Wang S, Nath N, Adlam M, Chellappan S. Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene. 1999;18:3501–3510
  19. Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem. 2003;278:47853–47861
  20. Wang S, Zhang B, Faller DV. Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. EMBO J. 2002;21:3019–3028
  21. Gamble SC, Chotai D, Odontiadis M, et al. Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene. 2007;26:1757–1768
  22. Sun L, Liu L, Yang XJ, Wu Z. Akt binds prohibitin 2 and relieves its repression of MyoD and muscle differentiation. J Cell Sci. 2004;117:3021–3029
  23. He B, Feng Q, Mukherjee A, et al. A repressive role for prohibitin in estrogen signaling. Mol Endocrinol. 2008;22:344–360
  24. Fan S, Wang J, Yuan R, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science. 1999;284:1354–1356

PII: S0959-8049(08)00867-8

doi: 10.1016/j.ejca.2008.10.021

European Journal of Cancer
Volume 45, Issue 5 , Pages 837-842 , March 2009

Article Tools